HBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-28), Harvard Bioscience's current share price is $3.16. Harvard Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.09. Harvard Bioscience's Cyclically Adjusted Price-to-FCF for today is 35.11.
The historical rank and industry rank for Harvard Bioscience's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Harvard Bioscience's highest Cyclically Adjusted Price-to-FCF was 81.80. The lowest was 10.22. And the median was 21.31.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Harvard Bioscience's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $0.016. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.09 for the trailing ten years ended in Mar. 2024.
The historical data trend for Harvard Bioscience's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 54.12 | 65.94 | 48.13 | 57.07 | 45.16 |
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Harvard Bioscience's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 3.16 | / | 0.09 | |
= | 35.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harvard Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Harvard Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.016 | / | 131.7762 | * | 131.7762 | |
= | 0.016 |
Current CPI (Mar. 2024) = 131.7762.
Harvard Bioscience Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201406 | 0.029 | 100.560 | 0.038 |
201409 | 0.004 | 100.428 | 0.005 |
201412 | 0.014 | 99.070 | 0.019 |
201503 | -0.047 | 99.621 | -0.062 |
201506 | -0.031 | 100.684 | -0.041 |
201509 | -0.022 | 100.392 | -0.029 |
201512 | 0.032 | 99.792 | 0.042 |
201603 | -0.027 | 100.470 | -0.035 |
201606 | 0.022 | 101.688 | 0.029 |
201609 | 0.084 | 101.861 | 0.109 |
201612 | 0.035 | 101.863 | 0.045 |
201703 | -0.024 | 102.862 | -0.031 |
201706 | 0.007 | 103.349 | 0.009 |
201709 | 0.054 | 104.136 | 0.068 |
201712 | -0.033 | 104.011 | -0.042 |
201803 | -0.002 | 105.290 | -0.003 |
201806 | 0.031 | 106.317 | 0.038 |
201809 | -0.046 | 106.507 | -0.057 |
201812 | 0.068 | 105.998 | 0.085 |
201903 | 0.050 | 107.251 | 0.061 |
201906 | 0.010 | 108.070 | 0.012 |
201909 | 0.074 | 108.329 | 0.090 |
201912 | 0.047 | 108.420 | 0.057 |
202003 | 0.069 | 108.902 | 0.083 |
202006 | 0.054 | 108.767 | 0.065 |
202009 | 0.027 | 109.815 | 0.032 |
202012 | 0.056 | 109.897 | 0.067 |
202103 | 0.018 | 111.754 | 0.021 |
202106 | 0.014 | 114.631 | 0.016 |
202109 | -0.028 | 115.734 | -0.032 |
202112 | -0.006 | 117.630 | -0.007 |
202203 | -0.060 | 121.301 | -0.065 |
202206 | -0.015 | 125.017 | -0.016 |
202209 | 0.005 | 125.227 | 0.005 |
202212 | 0.059 | 125.222 | 0.062 |
202303 | 0.037 | 127.348 | 0.038 |
202306 | 0.069 | 128.729 | 0.071 |
202309 | 0.093 | 129.860 | 0.094 |
202312 | 0.076 | 129.419 | 0.077 |
202403 | 0.016 | 131.776 | 0.016 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
James W Green | director, officer: Chief Executive Officer | 12525 CHADRON AVENUE, HAWTHORNE CA 90250 |
Alan I Edrick | director | 20200 SUNBURST STREET, CHATSWORTH CA 91311 |
Jennifer Cote | officer: Interim CFO | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746 |
Bertrand Loy | director | C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821 |
Thomas W Loewald | director | 81 WYMAN STREET, WALTHAM MA 02451 |
John F Kennedy | director | C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435 |
Katherine A. Eade | director | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Susan M. Steele | director | C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103 |
Kenneth Fletcher Olson | officer: Chief Operating Officer | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Michael A. Rossi | officer: Chief Financial Officer | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Yash Singh | officer: Executive Vice President | C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746 |
Jeffrey Duchemin | officer: Chief Executive Officer | 14 EASTLAND TERRACE, HAVERHILL MA 01830 |
Kamalam Unninayar | officer: Chief Financial Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Robert E. Gagnon | officer: Chief Financial Officer | C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493 |
George Uveges | director | C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464 |
From GuruFocus
By Marketwired • 07-27-2023
By sperokesalga sperokesalga • 05-02-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 04-18-2023
By Marketwired • 09-18-2023
By GuruFocusNews GuruFocusNews • 02-21-2022
By GuruFocusNews GuruFocusNews • 04-26-2022
By sperokesalga sperokesalga • 06-20-2023
By GF Value GF Value • 05-01-2021
By Marketwired Marketwired • 07-19-2021